The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example



Similar documents
Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine

The evolution and utility of a national stroke registry: the Swedish experience

Stent for Life Initiative How can we improve system delay and patients delay in STEMI

Management of Acute Coronary Syndrome / NSTEMI

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES

Success factors in Behavioral Medicine

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO

ACTION Registry - GWTG: Defect Free Care for Acute Myocardial Infarction Specifications and Testing Overview

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

Implementing a Prehospital 12-Lead Program

How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne

Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo

Description of problem Description of proposed amendment Justification for amendment ERG response

URN: Family name: Given name(s): Address:

Post-MI Cardiac Rehabilitation. Mark Mason Consultant Cardiologist Harefield Hospital Royal Brompton and Harefield NHS Foundation Trust

Listen to your heart: Good Cardiovascular Health for Life

The Role of Insurance in Providing Access to Cardiac Care in Maryland. Samuel L. Brown, Ph.D. University of Baltimore College of Public Affairs

Mission: Lifeline Recommendations for Criteria for STEMI Systems of Care

Redefining the NSTEACS pathway in London

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

EUROASPIRE II. European Action on Secondary and Primary Prevention through Intervention to Reduce Events

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness

STEMI Systems of Care

ACTION Registry GWTG Version 2.4

2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Quantifying Life expectancy in people with Type 2 diabetes

Aktuelle Literatur aus der Notfallmedizin

Māori Pathways to and Through Health Care for STEMIs in New Zealand. Summer Studentship Research by Ellie Tuzzolino- Smith

Value guided healthcare as a platform for industrial development in Sweden feasibility study

Utilizing the Cath Lab for Cardiac Arrest

Antiplatelet and Antithrombotics From clinical trials to guidelines

Design and principal results

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Main Effect of Screening for Coronary Artery Disease Using CT

Physician and other health professional services

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

Table 1 Performance Measures. Quality Monitoring P4P Yr1 Yr2 Yr3. Specification Source. # Category Performance Measure

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Summary Evaluation of the Medicare Lifestyle Modification Program Demonstration and the Medicare Cardiac Rehabilitation Benefit

ACO Name and Location Allina Health Minneapolis, Minnesota

DH Cardiac Rehabilitation Commissioning Pack: highlights and process. Prof Patrick Doherty BACR conference Liverpool 2010

Get With The Guidelines Best Practices: A look at reducing 30-day heart failure readmission rates

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Grant Opportunities. Providence Hood River Memorial Hospital Oregon Rural Healthcare Quality Network OREGON S EXPERIENCE

John Radcliffe Hospital, Oxford Heart Centre. Discharge advice after your coronary angiogram, angioplasty or stent insertion (PCI)

James F. Kravec, M.D., F.A.C.P

Cardiac Rehab and Primary Care: Avoiding Losses in Care Transitions. Neville Suskin Heart & Stroke Clinical Update 2012

The new Heart Failure pathway

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

CLINICAL & FINANCIAL BENEFITS OF ECG MANAGEMENT

Clinical Audit in Hospital Authority. Dr Betty Young Convenor for Clinical Audit, Hospital Authority

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

HealthCare Partners of Nevada. Heart Failure

Antiaggreganti. STEMI : cosa c è di nuovo? Heartline Genova Novembre 2015

Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada

Methodological Issues in Comparing Hospital Performance: Measures, Risk Adjustment, and Public Reporting

R.P. Zecchin*, J. Baihn, Y.Y. Chai, J. Hungerford, G. Lindsay, M. Owen, J. Thelander, D.L. Ross, C. Chow, A.R. Denniss. Westmead Hospital, Sydney,

The New Complex Patient. of Diabetes Clinical Programming

Care and EHR Integration Connecting Physical and Behavioral Health in the EHR. Tarzana Treatment Centers Integrated Healthcare

U.S. Food and Drug Administration

Kick off Meeting November 11 13, MERCY CLINIC EAST COMMUNITIES Management of Patients with Heart Failure (HF)

CARDIAC REHABILITATION

Networking for optimal treatment of STEMI and NSTEMI. European Stent for life Project

Stroke Rehabilitation Triage Severe Strokes

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head

Stroke Care First week

Florida Alcohol and Drug Abuse Association. Presented to the Behavioral Health Quarterly Meeting Pensacola, Florida April 23, 2014

Heart Center Packages

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

Population Health Management Program

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa Objectives. No disclosures, no conflicts

NHS outcomes framework and CCG outcomes indicators: Data availability table

Using Medicare Hospitalization Information and the MedPAR. Beth Virnig, Ph.D. Associate Dean for Research and Professor University of Minnesota

DEVICE RECALLS: The Era of Regulation and Outcome Metrics: Optimizing Benefits and Managing Risks

Prof. Dr. med. Roland Bingisser Head of Clinical Emergency Medicine University Hospital Basel. making?

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)

Transcription:

The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example Ulf Stenestrand, MD, PhD Department of Cardiology University Hospital Linköping Chairman RIKS-HIA

Register of Information and Knowledge about Swedish Heart Intensive care Admissions General information 8.. (out of hospitals in Sweden >. ICCU-admissions since 1 Annually. new admissions Annually. acute MI > % of CCU admissions Sweden Population million Size larger than Germany

Features of RIKS-HIA All consecutive patients at all participating hospitals are entered into the registry hours x 3 days Fully complies to European standard definitions of variables CARDS Based on a unique personal identification number given to every Swedish citizen at birth Non cardiac baseline information added by merging with other national registries Outcome such as new hospitalization or death is added by merging with other national registries this ensures 1% follow-up with no time limit

Data validity Information is entered over the Internet into RIKS-HIA or transferred from electronic patient records. The web-based interface has a number of logic controls for data being entered. Continuous validation and control of data is performed by an external monitor. These controls have detected on average % correct and non missing data entered

Purpose Develop acute coronary care by: Continuous information about patients (number & characteristics, therapy and outcome. Continuous feed-back about development and outcome at your own hospital Comparison with national guidelines, national standard and similar hospitals

Quality indicators = adherence to treatment goals according to guidelines How large is the variation in therapies between hospitals? Does the therapy change according to new guidelines? Does outcome improve with changed therapy? Does individual hospital s quality of care improve in relation to new treatment goals? Does individual hospital s quality of care affect outcome?

Quality indicators = adherence to treatment goals according to guidelines How large is the variation in therapies between hospitals? Does the therapy change according to new guidelines? Does outcome improve with changed therapy? Does individual hospital s quality of care improve in relation to new treatment goals? Does individual hospital s quality of care affect outcome?

Beta-blockers in MI < 8 year * # ( ' & % 1 Proportion beta-blockers by year # ( ' & % Proportion beta-blockers by hospital ' ( % &! ( %( ( & ' (% & ' &' ' ' & % (& ( %&%% % &' & ( '((%' % ' ( & & ' % Uppsala Clinical Research Centre (( & ( % & % '& &'(% ( %&( %( ' %' % & (' &

3 1 Measures in MI at different hospitals year ACE-inh./ A-block. 1 8 3 1 Betablocker Lipid lowering Coronary angiogram 3 3 1 1

Coronary angiogram in NSTEMI <8 years Discharged alive and at least 1 of the following alternatives: - Diabetes - Previous MI - ST-depression on EKG - Pulmonary rales - LVEF <% To receive a point % needed to receive angiogram =!. = A /.+!. :;. #1 -.+ = ; - A. 1. - /.+.+ @ -? -!! > = = -. /=.+ <- :;. 3 1.+ -! 8..+ - # 3 ++ #! 1 - (& % % & ' (. -!++/13 +!,+--+ -!++' Mean value Level to receive point RIKS-HIA annual report

Proportion coronary angiogram during hospital stay in MI Proportion coronary angiogram. ( ' & % ' ( % & ' Women '! < years '(&! Women - years B*(! Women >= years Men '! < years '(&! Men - years B*(! Men >= years.!.,!,,' Patients with MI discharged alive, Sweden 1- RIKS-HIA annual report

Lipid lowering drugs at discharge in MI <8 years Patients are discharged alive with a total-cholesterol >, or LDL-Cholesterol >, mmol/l To receive a point % was required 1.+ =. A / -!. - = /=.+ 1 /.+ - > =! = 3 8..+ @ -! ++?.+ <- ;.+ :;. #1 -! -. - - 1. A. :;. 3 - #!!.+ # = % % & ' ( + -!++ +!,+--+ -!++' Mean value Level to receive point 3% RIKS-HIA annual report

Development lipid lowering drugs at discharge by year, age and gender in MI 1 - Proportion coronary angiogram + ( ' & % ' ( % & ' Women < years Women - years Women >= years Men < years Men - years Men >= years '! '(&! B*(! '! '(&! B*(! Patients with MI discharged alive with total-cholesterol >, or LDL-Cholesterol >, mmol/l, Sweden 1- + C. D + -B&>B,+.!' RIKS-HIA annual report

Quality indicators = adherence to treatment goals according to guidelines How large is the variation in therapies between hospitals? Does the therapy change according to new guidelines? Does outcome improve with changed therapy? Does individual hospital s quality of care improve in relation to new treatment goals? Does individual hospital s quality of care affect outcome?

3-day mortality by year, age and gender in MI 1 - % % - 3-day mortality ' ( % & ' Women < years Women - years Women >= years Men < years Men - years Men >= years '! '(&! B*(! '! '(&! B*(! RIKS-HIA annual report ( % -

& F..CD Mortality % Year % & > Days E ' ( % & (.++.- MI patients - years. old in Sweden,'(&!, 1- RIKS-HIA annual report

3-day mortality by region year MI <8 years *& Mortality 3 days 1% % - 1% % % - =. / G South Stockholm South-east F North Central F. % -,!,' C-, D West RIKS-HIA annual report

1-year mortality by region year MI <8 years % *% Mortality 1 year!- % 1% 1% % % South Stockholm South-east - =. G / F Central West F.!-,!,& C-, D North RIKS-HIA annual report

3-day mortality by county and by hospital MI <8 years Mortality *& = :;. #1-1 :;. 3 <- ++ - A. #! = -. /=.+ -.+! > =.! - 1.+ # - 8..+. /! - -.+.+ -! /.+ @ -!? 1. = 3 - ; = A % % 1% 1% % >.-% Mortality by hospital % -,!,+ -B*+,'C-, D RIKS-HIA annual report

Quality indicators = adherence to treatment goals according to guidelines How large is the variation in therapies between hospitals? Does the therapy change according to new guidelines? Does outcome improve with changed therapy? Does individual hospital s quality of care improve in relation to new treatment goals? Does individual hospital s quality of care affect outcome?

Quality index Quality index is a relative index that aims to reflect the hospitals adherence to national (and ESC guidelines in acute MI. The index is based on measures that are recommended with high priority 1 3 (in a scale 1 to 1 in patients with indication and no contraindication for the treatment. 1 point was given to hospitals above the level of the ¼ that have the best adherence to national guideline previous year for each individual measure. A maximum of points can be achieved. RIKS-HIA annual report

Lipid lowering drugs at discharge in MI <8 years Patients are discharged alive with a total-cholesterol >, or LDL-Cholesterol >, mmol/l To receive a point % was required 1.+ =. A / -!. - = /=.+ 1 /.+ - > =! = 3 8..+ @ -! ++?.+ <- ;.+ :;. #1 -! -. - - 1. A. :;. 3 - #!!.+ # = % % & ' ( + -!++ +!,+--+ -!++' Mean value Level to receive point 3% RIKS-HIA annual report

Treatments at discharge in MI <8 years where the patients fulfill the treatment guidelines! /.+ @ - 3! > = = - ;? = -! #!. A = -!.+ / -. :;. #1 <- /=.+ - 1.+ 1. =.+ -! ++ 1 8..+ :;. 3 A. # -.+ -. % & ' ( -- +!,+--+ -!++' ASA 8% =? <- - =!. =! -.+ A.! - 1. 3 -..+ :;. #1 1 ; - -! @ - - :;. 3 /.+ /=.+! A # - 1.+ = ++.+ / 8..+. > = #! % & ' ( # -!++ +!,+--+ -!++' Beta-blocker 1% =!.+ /.+ <-! /! @ - -? :;. #1 1.. - > = -! 3.+! :;. 3 - - = = ; #! A = A. 1 1.+ - 8..+ -. # /=.+ ++.+. - % & ' ( H+-!++/13 H1G-- -!++ +!,+--+ -!++' +!,+--+ -!++' Clopidogrel 81% = - =! - - / /=.+! A! = - - 1.+ > = 1 @ - 1. /.+ 3 -. <-. :;. #1. -! ;.+? - ++ # 8..+ = :;. 3!.+.+ A. #! (( % & ' ( RAS-blocker % RIKS-HIA annual report

-. =?! - /=.+ - <- # ; /! =! 1.+ 1. A - = -. :;. 3 3 - -! 1. - 8..+.+.+ /.+ @ -.+ = -! A.. #! - ++ % & ' ( A& % A&+!.,+ C--+!-!++D -.+.! = A / :;. 3! =! - -.+ /=.+ - - = - > = 1 8..+ - =!?. # 1. ; /.+ @ - -! A. <- 1.+.+ -. 3 - #! ++ % & ' ( A % A+!.,+ C--+!-!++D RIKS-HIA annual report

Quality index based on recommended treatment according to national guidelines Quality index per hospital year! = -! / =! 1. - - A -. /.+ /=.+? 1.+ -. # > = ; -.+ = @ - :;. #1 3 A. <- 1.+.+ = -!! -. :;. 3 #! 8..+ ++ % & ' ( A' % A'+!.,+ C--+!-!++D RIKS-HIA annual report

Quality index development - 8..+ #! ++ :;. 3 -. Quality A' index ( ' & % /=.+ A - /.+ /= -!! 1.+.+-! =! <- ; @ - = # 3.+ A. -.+. 1? -! - 1.. = % & ' ( Quality index A& - RIKS-HIA annual report

Quality indicators = adherence to treatment goals according to guidelines How large is the variation in therapies between hospitals? Does the therapy change according to new guidelines? Does outcome improve with changed therapy? Does individual hospital s quality of care improve in relation to new treatment goals? Does individual hospital s quality of care affect outcome?

3-day mortality in MI related to hospital quality index. -% % Proportion dead 3 days % ' % % & 3% % % 1% % & ' B*( - - >= A Quality index & -% + A,'C!,--+ -!++D RIKS-HIA annual report

Quality indicators, quality index and patients health Adherence to guidelines varies! Average adherence to guidelines improves! Average outcome improves with changed care? Individual hospital s quality of care measured as quality index in relation to new treatment goals improve! Individual hospital s quality of care measured as quality index is related to outcome patients health!

Proportion of the last patients in respective target group that achieved the goal My hospital Average of best hospitals

Proportion of target population that received coronary angiogram. Patients in groups of 1 My hospital

On-line reports in RIKS-HIA RAS-blockade Reperfusion in STEMI

Quality reports in your own hospital On-line, includes everything that has been entered before midnight the previous evening. Mortality updated once a month by adding data from the National Population Registry Quarterly quality reports are automatically mailed to a free number of subscribers

Summary Complications and death are so uncommon that they cannot be used as quality indicators for individual hospitals. Adherence to guidelines and evidence based therapy is thus a better indicator of quality of care. Quality index is an attempt to summarize adherence to guidelines. Quality registries can help improving adherence to guidelines and thereby outcome and patient health

Thank you for your attention

Then Now Future Uniformed Uninterested Unequal - large regional differences Low compliance to guidelines Informed Interested, debate Less regional differences Better compliance to guidelines Halved mortality in 1 years More information Interested, natural No regional differences Total compliance to guidelines Further improved survival Even better quality support Thank you for your attention!

*! 3 :;. 3 8..+ ++ A. - @ - > = -. =.+ 1.+! <- -! - ; #!. = -? - /.+ 1. 13 min Symptom to PCI Median 1 min 8 min Delay by Hospital :;. 3 #! ; -! - > = ++ - -. 3 8..+! <-.+ 1 * min ER to PCI Median 1 min 1 min ' & % %' & & & ' =--IH3C-D % ' & IH3C-D..C-,(+D!=-- +-IH3,!,' - --..C-,(+D! - +-IH3,!,' - '--

Treatments at discharge in MI <8 years where the patients fulfill the treatment guidelines = -! -!! 1 -.!.+ A - /=.+ # ;? /.+ > = A. - 1..+ 1.+ 3 :;. #1 / <-. @ - = = -..+ = -! 8..+ :;. 3 ++ - #! % & ' ( JGIH3-=-!++/13 +!,+--+ -!++' LMWH/Heparin/ Fondaparinux or PCI < 1 day NSTEMI % A! =. = #.+ /=.+! - / - = 1. - 1.+ 1 - /.+? <- ;!.+! > = -. 8..+ @ - - -. :;. 3 A. = :;. #1 -! ++ 3 #!.+ '& % & ' ( IH3-+ -!++13G### +!,+--+ -!++' Primary PCI STEMI % - # - - 1. = / = - /=.+? 1. <-! /.+!! = A!.+ 1.+ > =.+ -. 8..+ @ -. - - :;. 3 ; = :;. #1 A. -! 3 ++.+ #! (% % & ' ( F+ -!++13G### +!,+--+ -!++' Primary PCI or thrombolysis STEMI 3% RIKS-HIA annual report